MediWound Ltd

NASDAQ:MDWD   3:59:41 PM EDT
4.42
+0.31 (+7.54%)
Products

MediWound Announces FDA Acceptance Of Biologics License Application For NexoBrid

Published: 09/16/2020 13:30 GMT
MediWound Ltd (MDWD) - Mediwound Announces FDA Acceptance of Biologics License Application for Nexobrid for the Treatment of Severe Thermal Burns.
Mediwound Ltd - FDA Assigned a Prescription Drug User Fee Act Target Date of June 29, 2021 for Nexobrid.
Mediwound - in Addition, FDA Communicated That It is Not Currently Planning to Hold an Advisory Committee Meeting to Discuss Application for Nexobrid.